Hutchmed (China) logo

Hutchmed (China)(NASDAQ) HCM

Market Cap$2.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+8%
5 Year-58%
1 Year-7%
1 Month+21%
Premium Feature
Moneyball Superscore
62/100
$14.68
+0.34%
+0.05Today
After hours$14.63-$0.05 (-0.34%)
Hutchmed (China) last closing stock price
MetricPriceDate
Last closeUSD 14.632026-09-30
Hutchmed (China) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.81%USD 14.372026-09-23
1 month+20.71%USD 12.122026-08-31
3 month+27.88%USD 11.442026-07-02
Year to date+9.75%USD 13.332025-12-31
1 year-7.11%USD 15.752025-09-30
3 year-13.64%USD 16.942023-09-29
5 year-58.47%USD 35.232021-10-01
Since inception+8.37%USD 13.502016-03-18

Hutchmed (China) Financials at a Glance

Market Cap

$2.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$549.12M

Net Income (TTM)

$17.88M

EPS (TTM)

$0.10

P/E Ratio

143.85

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$14.68

Volume

70,990.357

Open

$14.63

Previous Close

$14.57

Daily Range

$14.57 - $14.80

52-Week Range

$9.77 - $16.40

Estimated Earnings Date

Mar 4, 2027

HCM News

featured-transcript-logo

Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript

Motley Fool TranscriptionJul 30, 2019
Chart going down with man looking

Why Chi-Med Stock Is Tanking Today

Keith SpeightsJun 28, 2019

HCM: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hutchmed (China)

HUTCHMED (China) Limited is a biopharmaceutical firm focused on the discovery, development, and commercialization of innovative targeted and immune-based therapies for various cancers and immune-related disorders. The company operates primarily in oncology and immunology, with a diverse pipeline of promising treatments.

Products and Services
  • Savolitinib: Targeting non-small cell lung cancer and other cancers
  • Fruquintinib: Investigated for colorectal and breast cancers
  • Surufatinib: Applicable to neuroendocrine tumors and solid tumors
Growth Outlook
  • Strong pipeline with multiple candidates in late-stage development
  • Strategic collaborations with major pharmaceutical companies enhance market reach
  • Increasing global demand for innovative cancer therapies supports growth potential
Financial Highlights
  • Recent quarterly revenue of $139.1 million, showing stability
  • Trailing twelve months (TTM) net income margin of 3.26%
  • Current ratio of 5.64 indicates strong liquidity position
HUTCHMED (China) Limited is well-positioned in the biopharmaceutical sector, focusing on innovative treatments for cancer and immune-related disorders. The company's diverse product pipeline, including key therapies like Savolitinib and Fruquintinib, demonstrates its commitment to addressing significant medical needs. Recent financial performance indicates stability, with a notable revenue figure and a healthy liquidity position, suggesting the company can effectively manage its operations and invest in future growth. Strategic partnerships with leading pharmaceutical firms further enhance its market presence and potential for expansion. Overall, HUTCHMED represents a compelling opportunity within the healthcare sector, driven by innovation and a robust growth strategy.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,796

CEO

Chig Fung Cheng

Website

www.hutch-med.com

Headquarters

Hong Kong, HK

HCM Financials

Key Financial Metrics (TTM)

Gross Margin

0.20%

Operating Margin

-6.33%

Net Income Margin

3.26%

Return on Equity

1.43%

Return on Capital

-4.10%

Return on Assets

1.03%

Earnings Yield

0.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

174.47M

Volume

70.99K

Avg. Volume

68.86K

Financials (TTM)

Gross Profit

$1.11M

Operating Income

-$34.78M

EBITDA

-$20.52M

Operating Cash Flow

$20.46M

Capital Expenditure

-$10.51M

Free Cash Flow

$9.95M

Cash & ST Invst.

$1.38B

Total Debt

$94.51M

Hutchmed (China) Performance Analysis

Hutchmed (China) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 425,902,33719.4%
20232023-12-31USD 837,270,55596.6%
20242024-12-31USD 630,517,095-24.7%
20252025-12-31USD 549,962,669-12.8%
Hutchmed (China) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.5%
Q42025-12-31N/A
Q12026-03-312.8%
Q22026-06-30N/A
Hutchmed (China) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.1373.0%
20232023-12-31USD 0.58N/A
20242024-12-31USD 0.22-62.7%
20252025-12-31USD 2.621113.2%
Hutchmed (China) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-99.6%
Q42025-12-31N/A
Q12026-03-31736.4%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$139.14M

+0.2%

Gross Profit

$23.67M

-57.0%

Gross Margin

17.01%

N/A

Market Cap

$2.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.42M

N/A

Employees

1,796

N/A

Net Income

$7.96M

-96.5%

EBITDA

$3.97M

+205.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.38B

+0.8%

Total Debt

$94.51M

-6.2%

Accounts Receivable

$117.56M

-20.0%

Inventory

$40.84M

-15.7%

Long Term Debt

$72.10M

+1.5%

Short Term Debt

$22.41M

-24.6%

Return on Assets

1.03%

N/A

Return on Invested Capital

-2.38%

N/A

Free Cash Flow

$3.30M

+108.0%

Operating Cash Flow

$6.11M

+116.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SUPNSupernus Pharmaceuticals, Inc.
$42.18-2.00%
BHCBausch Health Companies Inc.
$5.73-1.72%
MLYSMineralys Therapeutics, Inc.
$23.72-5.61%
PRGOPerrigo Company plc
$14.02-5.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About HCM

What is the current price of Hutchmed (China)?

Hutchmed (China) is trading at $14.57 per share.

What is the 52-week range for Hutchmed (China)?

Over the past 52 weeks, Hutchmed (China) has traded between $9.77 and $16.40.

How much debt does Hutchmed (China) have?

As of the most recent reporting period, Hutchmed (China) reported total debt of $97.89M.

How much cash does Hutchmed (China) have on hand?

Hutchmed (China) reported $71.33M in cash and cash equivalents in its most recent financial results.

What is Hutchmed (China)’s dividend yield?

Hutchmed (China) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services